DRG Market Assessment reports

Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of CD treatment is to induce and…

Like other retinal disease therapy markets, the retinal vein occlusion (RVO) with macular edema (ME) market in the United States is unique in that it is dominated by Genentech’s Avastin, an…

Clarivate Epidemiology’s coverage of soft tissue sarcoma (STS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

MARKET OUTLOOK NASH is a chronic disease that causes extensive and potentially fatal liver fibrosis; it is a leading cause of liver transplant. Significant increases in rates of diabetes and…

Colorectal cancer, a major public health concern in China, is expected to become the second-most-common form of cancer there by 2029, behind only lung cancer. The treatment of metastatic colorectal…

MARKET OUTLOOK China has the highest incidence of gastric cancer (gastric and gastroesophageal junction adenocarcinoma) in the world, and therapeutic options are limited. Only two targeted…

Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance,…

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 400 currently available and novel biosimilar products, detailing…

MARKET OUTLOOK With the launch of five adalimumab biosimilars into the European market since October 2018—Amgevita (Amgen), Imraldi (Biogen), Hulio (Mylan), Hyrimoz (Sandoz), and Idacio (…

The market for prescription migraine therapies comprises an array of prescription acute and prophylactic treatments and fosters a large and dynamic pipeline. In the acute space, we anticipate the…

Hepatocellular carcinoma (HCC) is a primary malignancy of the liver that commonly arises from underlying liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx), an angiogenesis inhibitor, was…

Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, AML treatment has been dominated by…